author-photo

Jacob Schlossman

University of California, Los Angeles

9

Papers

26

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Rate of change in maximum 18 F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas

2020 Journal of Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (8)
Estimated clinical efficacy and radiographic response characteristics of PD1 inhibition in newly diagnosed and recurrent glioblastoma in clinical practice: A report from the iRANO Working Group.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.

2020 Neurosurgery
Show All
- Source
- Cite
- Save
Citations (1)
NIMG-17. VALIDATION OF DIFFUSION MRI AS AN IMAGING BIOMARKER FOR BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA IN A RANDOMIZED PHASE III TRIAL OF BEVACIZUMAB WITH OR WITHOUT VB-111 (GLOBE)

2020 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma

2019 Journal of Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (15)
Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without bevacizumab or bevacizumab monotherapy.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)